Diabetes Mellitus (DM) is a multi-factorial chronic health condition that affects a large part of population and according to the World Health Organization (WHO) the number of adults living with diabetes is expected to increase. Since type 2 diabetes mellitus (T2DM) is suffered by the majority of diabetic patients (around 90-95%) and often the mono-target therapy fails in managing blood glucose levels and the other comorbidities, this review focuses on the potential drugs acting on multi-targets involved in the treatment of this type of diabetes. In particular, the review considers the main systems directly involved in T2DM or involved in diabetes comorbidities. Agonists acting on incretin, glucagon systems, as well as on peroxisome proliferation activated receptors are considered. Inhibitors which target either aldose reductase and tyrosine phosphatase 1B or sodium glucose transporters 1 and 2 are taken into account. Moreover, with a view at the multi-target approaches for T2DM some phytocomplexes are also discussed.
Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs / A. Artasensi, A. Pedretti, G. Vistoli, L. Fumagalli. - In: MOLECULES. - ISSN 1420-3049. - 25:8(2020 Apr). [10.3390/molecules25081987]
Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs
A. ArtasensiPrimo
Writing – Original Draft Preparation
;A. PedrettiSecondo
Writing – Review & Editing
;G. VistoliPenultimo
Writing – Review & Editing
;L. Fumagalli
Ultimo
Conceptualization
2020
Abstract
Diabetes Mellitus (DM) is a multi-factorial chronic health condition that affects a large part of population and according to the World Health Organization (WHO) the number of adults living with diabetes is expected to increase. Since type 2 diabetes mellitus (T2DM) is suffered by the majority of diabetic patients (around 90-95%) and often the mono-target therapy fails in managing blood glucose levels and the other comorbidities, this review focuses on the potential drugs acting on multi-targets involved in the treatment of this type of diabetes. In particular, the review considers the main systems directly involved in T2DM or involved in diabetes comorbidities. Agonists acting on incretin, glucagon systems, as well as on peroxisome proliferation activated receptors are considered. Inhibitors which target either aldose reductase and tyrosine phosphatase 1B or sodium glucose transporters 1 and 2 are taken into account. Moreover, with a view at the multi-target approaches for T2DM some phytocomplexes are also discussed.File | Dimensione | Formato | |
---|---|---|---|
molecules-25-01987.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
849.5 kB
Formato
Adobe PDF
|
849.5 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.